In 2021, Zeng et al. retrospectively analyzed 130 patients with stage IIIA-IVB NSCLC receiving immunotherapy combined with chemotherapy, and developed a PFS nomogram based on 4 pivotal factors: bone metastasis, dNLR, smoking status, and PD-L1 status. Here, CD274 is linked to non-small cell lung carcinoma.